| 4904 |
Setting up PFMS for NTEP |
02/05/2023 |
|
| 4905 |
Making payments in PFMS |
02/05/2023 |
|
| 4906 |
Generating expenditure reports |
02/05/2023 |
|
| 4514 |
Roles and responsibilities of stakeholders under Jan Andolan |
05/05/2023 |
|
| 93 |
Epidemiological Terms used in TB |
08/05/2023 |
|
| 4923 |
Elimination Vs Eradication |
08/05/2023 |
|
| 975 |
Second Line anti TB drugs |
09/05/2023 |
|
| 1094 |
Shorter oral Bedaquiline-containing MDR/RR-TB regimen |
09/05/2023 |
|
| 4930 |
Shorter oral Bedaquiline-containing MDR/RR-TB regimen: Evidence |
09/05/2023 |
|
| 1109 |
Regimen, Duration and Dosage for Isoniazid [H] Mono/Poly DR-TB Regimen |
09/05/2023 |
|
| 4932 |
EVIDENCE FOR ISONIAZID[H] MONO/POLY DR-TB REGIMEN |
09/05/2023 |
|
| 223 |
IPC practices required at a DMC |
11/05/2023 |
|
| 1057 |
Follow-up Monitoring for individuals taking TPT |
11/05/2023 |
|
| 4935 |
TPT in Pregnancy |
11/05/2023 |
|
| 4936 |
Post-treatment TPT in PLHIV |
11/05/2023 |
|
| 4938 |
Treatment outcomes after TPT |
11/05/2023 |
|
| 1058 |
Treatment Adherence for individuals taking TPT |
11/05/2023 |
|
| 4941 |
Monitoring indicators for TPT |
12/05/2023 |
|
| 254 |
Regimen for TPT |
12/05/2023 |
|
| 4943 |
Management of missed doses in TPT |
12/05/2023 |
|
| 1118 |
Preventive Treatment for Contacts of DR-TB Patients |
12/05/2023 |
|
| 1644 |
Root cause analysis for Low Performance in Percentage of Target TB Notification Achieved |
13/05/2023 |
|
| 33 |
TB Preventive Therapy |
13/05/2023 |
|
| 4952 |
Incentivising the TB Champions |
15/05/2023 |
|
| 4953 |
Monitoring of work done by TB Champions |
15/05/2023 |
|
| 4954 |
Empowering the TB Champions |
15/05/2023 |
|
| 743 |
Treatment Support Plan |
15/05/2023 |
|
| 4498 |
General principles of financial management |
15/05/2023 |
|
| 4960 |
Financial Management - overview and objectives |
15/05/2023 |
|
| 4962 |
Essential checks by STO/DTO |
15/05/2023 |
|
